Ascendia

  MARKET NEWS

TILT Biotherapeutics Announces First Patient Dosed in Phase 1 Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination With Checkpoint Inhibitor
Empty Capsules Market is Expected to Reach $4.9 Billion
First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
SERB Pharmaceuticals & SFJ Pharmaceuticals Announce US Partnership for Ticagrelor Reversal Agent
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability With CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
Alvotech Enters Commercialization Agreement With Polifarma for Proposed Biosimilar to Eylea

  FEATURED EDITORIAL

  COMPANY PROFILE

Mitsubishi Gas Chemical (MGC) is a leading company in the field of oxygen barrier and absorbing polymers. Based on these technologies and experiences, MGC launched new multilayer plastic vial named OXYCAPT in 2019. It has achieved excellent oxygen and ultraviolet (UV) barrier, high water vapor barrier, very low extractables, high pH stability, low protein adsorption, high transparency, high break resistance, easier disposability, lighter weight, etc. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Cellular Origins Partners With ScaleReady to Simplify, Standardize & Automate Cell Therapy Manufacturing

Cellular Origins Partners With ScaleReady to Simplify, Standardize & Automate Cell Therapy Manufacturing

Cellular Origins recently announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf that brings together process development expertise, tools, and technologies for scalable CGT….

Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering

Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering

New collaboration combines Mekonos’ novel ex vivo delivery platform with bit.bio’s unique opti-ox™ precision cellular reprogramming technology to accelerate the development of human cells for research, drug discovery and….

Evonetix Delivers First Chip-Synthesized DNA to the University of Cambridge

Evonetix Delivers First Chip-Synthesized DNA to the University of Cambridge

Evonetix recently announced DNA synthesized using its unique semiconductor chip technology was delivered to the Department of Chemical Engineering and Biotechnology at the University of Cambridge. This milestone marks the start of the next stage of development of the….

Syneos Health to be Acquired for Approximately .1 Billion

Syneos Health to be Acquired for Approximately $7.1 Billion

Syneos Health, Inc. recently announced it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management, Patient Square Capital….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

  WHITEPAPERS & WEBINARS

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

Particle Works is thrilled to announce the launch of a new Application Note that delves into the advancement of nanoparticles as carriers for targeted drug delivery. Developing nanoparticles for this purpose can be intricate and demanding, necessitating consistent, cost-effective, and …

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, extrusion-spheronization (E-S) offers pharmaceutical companies a robust technique to manufacture today’s most complex therapeutics. Manufacturing oral solid dose (OSD) APIs into spheres via E-S is not new. What is new is that in the …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 24 – Parenteral Contract Manufacturing
May 31 – Controlled Release